DOCSLIB.ORG

Appendix: Drug Dosing in Renal Failure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

44. Drug dosage in renal failure Appendix: Drug dosing in renal failure Abbreviations used: ACE: angiotensin-converting enzyme AV: atrioventricular BUN: blood urea nitrogen CCr: Creatinine clearance CAPD: continuous ambulatory peritoneal dialysis CHF: congestive heart failure CMV: cytomegalovirus CNS: central nervous system CRRT: continuous renal replacement therapy CSA/FK: cyclosporine A and tacrolimus CVD: cardiovascular disease CVVH: Continuous venovenous hemofiltration DVT: deep vein thrombosis ESRD: end-stage renal disease GI: gastrointestinal GFR: glomerular filtration rate HBV: hepatitis B virus HD: hemodialysis HDL: high-density lipoprotein HIT: heparin-induced thrombocytopenia HSV: herpes simplex virus INR: international normalized ratio IV: intravenous MI: myocardial infarction MMF: mycophenolate mofetil NA: not applicable NC: No data: no change required NSAIDs: nonsteroidal anti-inflammatory drugs TB: tuberculosis TDM: therapeutic drug monitoring VD: volume of distribution VZV: varicella zoster virus. 919 920 Table 2 . Antibacterial agents % of drug Dosage adjustment for renal failure with GFR Method of dosage adjustment Drug Normal dosage excreted (ml/min): Comments renally >50 10−50 <10 HD CAPD CVVH Aminoglycosides Group toxicity: all agents in this group are nephrotoxic and ototoxic; ototoxicity is worse when the patient is hyperbilirubinemic; measure serum levels for efficacy and toxicity; peritoneal absorption increases with presence of inflammation. V increases with edema, obesity, and ascites D Streptomycin 7.5 mg/kg q. 12 hr 60% q. 24 hr q. 24−72 hr q. 72−96 hr May be less nephrotoxic than other Half normal 20−40 mg/L/ Dose for GFR (1.0 g q. 24 hr members of class dose after day 10−50 ml/min; for TB) dialysis measure levels Kanamycin 7.5 mg/kg q. 8 hr 50%−90% 60%−90% q. 30%−70% q. 20%−30% q. Avoid once-daily dosing in patients Half full 15−20 mg/L/ Dose for GFR 12 hr; 12−18 hr; 100% 24−48 hr; 100% with CCr < 30−40 ml/min or in patients dose after day 10−50 ml/min; 100% q. 12− q. 24−48 hr q. 48−72 hr with acute renal failure or an uncertain dialysis measure levels 24 hr level of kidney function Gentamicin 1.7 mg/kg q. 8 hr 95% 60%−90% q. 30%−70% q. 20%−30% q. Concurrent penicillin treatment may Half full 3−4 mg/L/day Dose for GFR 8−12 hr; 100% 12−18 hr; 100% 24−48 hr; 100% result in subtherapeutic aminoglycoside dose after 10−50 ml/min; q. 12−24 hr q. 24-48 hr q. 48−72 hr levels dialysis measure levels Peak, 6−8; trough, < 2 Tobramycin 1.7 mg/kg q. 8 hr 95% 60%−90% q. 30−70% q. 20−30% q. Concurrent penicillin treatment may Half full 3−4 mg/L/day Dose for GFR 8−12 hr; 100% 12−18 hr; 100% 24−48 hr; 100% result in subtherapeutic aminoglycoside dose after 10−50 ml/min, BENNETT & OLYAEI q. 12−24 hr q. 24-48 hr q. 48−72 hr levels dialysis measure levels Peak, 6−8; trough, < 2 Netilmicin 2 mg/kg q. 8 hr 95% 50%−90% q. 20−60% q 12 10−20% q. May be less ototoxic than other mem- Half full 3−4 mg/L/day Dose for GFR 8−12 hr; 100% hr; 100% q 24−48 hr; 100% bers of class dose after 10−50 ml/min; q. 12−24 hr 24−48 hr q 48−72 hr Peak, 6−8; trough, < 2 dialysis measure levels Amikacin 7.5 mg/kg q. 12 hr 95% 60%−90% q. 30−70% q. 20−30% q. Monitor levels Half full 15−20 mg/L/ Dose for GFR 12 hr: 100% q. 12−18 hr; 100% 24−48 hr; 100% Peak, 20−30; trough, <5 dose after day 10−50 ml/min; 12−24 hr q. 24−48 hr q. 48−72 hr dialysis measure levels Cephalosporins (oral) Group toxicity: Adverse effects: coagulation abnormalities, transitory elevation of BUN, rash, and serum sicknesslike syndrome Cefaclor 250−500 mg 70% 100% 100% 50% Group toxicity 250 mg after 250 mg q. 8− No data q. 8 hr dialysis 12 hr Cefadroxil 500 mg to 1 g q. 80% 100% 100% 50% Group toxicity 0.5−1.0 g 0.5 g/day No data 12 hr after dialysis Cefixime 200−400 mg q. 85% 100% 100% 50% Group toxicity 300 mg after 200 mg/day Not recom- 12 hr dialysis mended Cefpodoxime 200 mg q. 12 hr 30% 100% 100% 100% Group toxicity 200 mg after Dose for No data dialysis GFR<10 ml/min Ceftibuten 400 mg q. 24 hr 70% 100% 100% 50% Group toxicity 300 mg after No data: Dose Dose for GFR dialysis for GFR <10 10−50 ml/min ml/min Cefuroxime 250−500 mg 90% 100% 100% 100% Malabsorbed in presence of H2 blockers; Dose after Dose for No data axetil q. 8 hr absorbed better with food dialysis GFR<10 ml/min Cephalexin 250−500 mg 95% 100% 100% 100% Rare allergic interstitial nephritis; ab- Dose after Dose for No data q. 8 hr sorbed well when given intraperitone- dialysis GFR<10 ml/min ally; may cause bleeding from impaired prothrombin biosynthesis % of drug Dosage adjustment for renal failure with GFR Method of dosage adjustment Drug Normal dosage excreted (ml/min): Comments renally >50 10−50 <10 HD CAPD CVVH Cephradine 250−500 mg 100% 100% 100% 50% Rare allergic interstitial nephritis; ab- Dose after Dose for No darta q. 8 hr sorbed well when given intraperitone- dialysis GFR<10 ml/min ally; may cause bleeding from impaired prothrombin biosynthesis Cephalosporins (IV) Group toxicity: may cause coagulation abnormalities, transitory elevation of BUN, rash, and serum sicknesslike syndrome Cefamandole 1−2 g IV q. 6−8 hr 100% q. 6 hr q. 8 hr q. 12 hr Group toxicity 0.5−1.0 g 0.5−1.0 g q. Dose for GFR after dialysis 12 hr 10−50 ml/min Cefazolin 1−2 g IV q. 8 hr 80% q. 8 hr q. 12 hr q. 12−24 hr Group toxicity 0.5−1.0 g 0.5 g q. 12 hr Dose for GFR after dialysis 10−50 ml/min Cefepime 1−2 g IV q. 8 hr 85% q. 8−12 hr q. 12 hr q. 24 hr Group toxicity 1 g after Dose for GFR < Not recom- dialysis 10 ml/min mended Cefmetazole 1−2 g IV q. 8 hr 85% q. 8 hr q. 12 hr q. 24 hr Group toxicity Dose after Dose for GFR Dose for GFR dialysis <10 ml/min 10−50 ml/min Cefoperazone 1−2 g IV q. 12 hr 20% No renal adjustment required. Displaced from protein by bilirubin; may 1 g after NC NC prolong prothrombin time; reduce dose dialysis failure 44. Drugdosageinrenal by 50% in patients with jaundice Cefotaxime 1−2 g IV q. 6−8 hr 60% q. 8 hr q. 12 hr q. 12−24 hr Group toxicity 1 g after 1 g/day 1 g q. 12 hr dialysis Cefotetan 1−2 g IV q. 12 hr 75% q. 12 hr q. 12−24 hr q. 24 hr Group toxicity 1 g after 1 g/day 750 mg q. 12 hr dialysis Cefoxitin 1−2 g IV q. 6 hr 80% q. 6 hr q. 8−12 hr q. 12 hr May produce false increase in serum 1 g after 1 g/day Dose for GFR creatinine level by interference with dialysis 10−50 ml/min assay Ceftazidime 1−2 g IV q. 8 hr 70% q. 8 hr q. 12 hr q. 24 hr Group toxicity 1 g after 0.5 g/day Dose for GFR dialysis 10−50 ml/min Ceftriaxone 1−2 g IV q. 24 hr 50% No renal adjust- Dose after di- 750 mg q. 12 hr Dose for ment required alysis GFR 10−50 ml/min Cefuroxime 0.75−1.5 g IV q. 90% q. 8 hr q. 8−12 hr q. 12−24 hr Absorbed well when given intraperito- Dose after Dose for GFR 1.0 g q. 12 hr sodium 8 hr neally; may cause rare allergic interstitial dialysis <10 nephritis; may cause bleeding from impaired prothrombin biosynthesis Clindamycin 150−450 mg q. 10% No renal adjustment required Increase CSA/FK level NC NC NC 8 hr Imipenem- 250−500 mg IV 50% 500 mg q. 8 hr 250−500 q. 250 mg q. 12 hr Causes seizures in ESRD; nonrenal clear- Dose after Dose for GFR Dose for GFR cilastatin q. 6 hr 8−12 hr ance in acute renal failure is less than dialysis <10 ml/min 10−5 ml/min in chronic renal failure; administer with cilastin to prevent nephrotoxicity of renal metabolite Macrolides Azithromycin 250−500 mg q. 6% No renal adjustment required No drug-drug interaction with CSA/KF NC NC NC 24 hr Clarithromycin 500 mg q. 12 hr 20% No renal adjustment required NC NC NC 921 Dirithromycin 500 mg q. 24 hr No renal adjustment required Nonenzymatically hydrolyzed to active NC NC Dose for GFR compound erythromycylamine. 10−50 ml/min 922 % of drug Dosage adjustment for renal failure with GFR Method of dosage adjustment Drug Normal dosage excreted (ml/min): Comments renally >50 10−50 <10 HD CAPD CVVH Erythromycin 250−500 mg q. 15% No renal adjustment required Increase CSA/FK levels; avoid in NC NC NC 8 hr transplant patients Meropenem 1 g IV q. 8 hr 65% 1 g q. 8 hr 0.5−1g q. 12 hr 0.5−1 g q.
Recommended publications
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0

    35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0

    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies

    Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies

    molecules Article Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies Pradeep Kumar Bolla 1 , Carlos A. Meraz 1, Victor A. Rodriguez 1, Isaac Deaguero 1, Mahima Singh 2 , Venkata Kashyap Yellepeddi 3,4 and Jwala Renukuntla 5,* 1 Department of Biomedical Engineering, College of Engineering, The University of Texas at El Paso, 500 W University Ave, El Paso, TX 79968, USA 2 Department of Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA 3 Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, UT 84112, USA 4 Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA 5 Department of Basic Pharmaceutical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC 27240, USA * Correspondence: [email protected] Received: 9 August 2019; Accepted: 28 August 2019; Published: 29 August 2019 Abstract: Global incidence of superficial fungal infections caused by dermatophytes is high and affects around 40 million people. It is the fourth most common cause of infection. Clotrimazole, a broad spectrum imidazole antifungal agent is widely used to treat fungal infections. Conventional topical formulations of clotrimazole are intended to treat infections by effective penetration of drugs into the stratum corneum. However, drawbacks such as poor dermal bioavailability, poor penetration, and variable drug levels limit the efficiency. The present study aims to load clotrimazole into ufosomes and evaluate its topical bioavailability. Clotrimazole loaded ufosomes were prepared using cholesterol and sodium oleate by thin film hydration technique and evaluated for size, polydispersity index, and entrapment efficiency to obtain optimized formulation.
  • Characterising the Risk of Major Bleeding in Patients With

    Characterising the Risk of Major Bleeding in Patients With

    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
  • Producing In-Situ Nanoparticles of Griseofulvin Using Supercritical Antisolvent Methodology

    Producing In-Situ Nanoparticles of Griseofulvin Using Supercritical Antisolvent Methodology

    University of Rhode Island DigitalCommons@URI Open Access Dissertations 2013 Producing In-Situ Nanoparticles of Griseofulvin using Supercritical Antisolvent Methodology Pratik Sheth University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Sheth, Pratik, "Producing In-Situ Nanoparticles of Griseofulvin using Supercritical Antisolvent Methodology" (2013). Open Access Dissertations. Paper 25. https://digitalcommons.uri.edu/oa_diss/25 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. PRODUCING IN-SITU NANOPARTICLES OF GRISEOFULVIN USING SUPERCRITICAL ANTISOLVENT METHODOLOGY BY PRATIK SHETH A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN BIOMEDICAL AND PHARMACEUTICAL SCIENCES UNIVERSITY OF RHODE ISLAND 2013 DOCTOR OF PHILOSOPHY DISSERTATION OF PRATIK SHETH APPROVED: Dissertation Committee: Major Professor M. Serpil Kislalioglu Ph.D David Worthen Ph.D. Michael L. Greenfield Ph.D Nasser H. Zawia Ph.D DEAN OF THE GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2013 ABSTRACT Poor aqueous solubility of drug candidates is a major challenge for the pharmaceutical scientists involved in drug development. Particle size reduction to nano scale appears as an effective and versatile option for
  • Acid-Catalysed Hydroaminations

    Acid-Catalysed Hydroaminations

    Acid-Catalysed Hydroaminations A thesis submitted to Cardiff University by Laura Henderson MChem (Hons.) In candidature of the degree of Doctor of Philosophy School of Chemistry Cardiff University UMI Number: U557419 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U557419 Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Acknowledgments First of all I would like to thank Prof. David W. Knight, for all his support, great ideas and seemingly endless breadth of knowledge that made this project possible. Secondly, I would also like to thank Dr. Andrew C. Williams for all the support and advice he has given over the last three years. I am grateful to the many students whose have contributed towards this thesis; they were all a joy to work with. In particular, I want to thank Nena Christiansen, Jon Williams and Rhian Courtney for their work. I want to thank Dr Rob Jenkins, Robin Hicks and Dave Walker for all of their mass spec, and NMR support over the years. I also want to thank Dr John Brazier and Dr Jacky Yau for all the advice and help that they gave, and endless enthusiasm that they have shown.
  • UTROGESTAN 100Mg Capsules Progesterone

    UTROGESTAN 100Mg Capsules Progesterone

    NEW ZEALAND DATA SHEET UTROGESTAN 100mg capsules Progesterone 1 PRODUCT NAME UTROGESTAN 100MG CAPSULES 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Soft, round, slightly yellow capsule containing a whitish oily suspension of 100 mg progesterone (micronised). Excipient(s) with known effect: Soya lecithin For full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Capsules, soft 4 CLINICAL PARTICULARS 4.1 Therapeutic indications UTROGESTAN 100 mg capsule is indicated in adults, via the oral route, for: Hormone replacement therapy • Adjunctive use with an oestrogen in postmenopausal women with an intact uterus (for hormone replacement therapy [HRT]) 4.2 Dose and method of administration Dosage The recommended dose is as follows, according to the indication: Oral Route • In the treatment of menopause: oestrogen alone therapy is not recommended on its own in menopausal women with an intact uterus. The usual dose is 200 mg/day at bedtime at least 12 to 14 days per month, i.e. on days 15 to 26 of each cycle or in the last 2 weeks of each treatment sequence of oestrogen therapyfollowed by approximately one week without any replacement therapy and during which withdrawal bleeding may occur. Alternatively 100 mg can be given at bedtime, from days 1 to 25 of each cycle, withdrawal bleeding being less with this treatment schedule. Method of Administration This product is intended only for oral use. UTROGESTAN 100 mg should not be taken with food; it is preferable to take the capsules in the evening at bedtime. UTROGESTAN 100mg caps UTROGEST005 Jan 2018 Page 1 of 9 NEW ZEALAND DATA SHEET Oral Route Each capsule of UTROGESTAN 100 mg must be swallowed with a little water.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Mercury Poisoning Manifested Acrodynia, Reported in Four Old Boy in Michigan Ten Day After the Inside of His Heme Painted

    Mercury Poisoning Manifested Acrodynia, Reported in Four Old Boy in Michigan Ten Day After the Inside of His Heme Painted

    TOXIC INFECTIVE DISORDERS MERCURY POISONING AND LATEX PAINT Mercury poisoning manifested as acrodynia, reported in a four year old boy in Michigan ten day after the inside of his heme was painted with 64 liters of interior latex paint containing phenylmercurie acetate, prompted an investigation by the Division of Environmental Hazards and Health Effects, Centers for Disease Control, Atlanta, GA. Nineteen families were recruited from a list of more than 100 persons who called the Michigan Department of Public Health after a press release announced that some interior latex paint contained more than the recommended limit of mercury of 1.5 nmol per liter. Ihe median mercury content of the paint in 29 cans sanpled from the exposed households was 3.8 nmol per liter. Hie concentrations of mercury in the air sanples obtained from homes of exposed families were significantly higher than in the unexposed households. Urinary mercury concentrations were significantly higher among the exposed persons than among unexposed persons (4.7 nmol of mercury per millimole of creatinine compared to 1.1 nmol per millimole). These mercury concentrations in exposed persons have been associated with synptcmatic mercury poisoning. (Agocs MM, Etzel RA et al. Mercury exposure from interior latex paint. N Engl J Med Oct 18, 1990; 323:1096-1101). OCMVENT. Exposed children had the highest urinary mercury concentrations and young children may be at increased risk since vapors containing mercury are heavier than indoor air and tend to settle toward the floor. Individual exposure to mercury varies with the time spent in painted rooms, the depth and frequency of inhalation, the degree of ventilation in the room, and the likely decrease in mercury vapors over time.
  • Microgram Journal, Vol 3, Number 2

    Microgram Journal, Vol 3, Number 2

    MICROGRAM Laboratory Operations Division Office Of Science And Drug Abuse Prevention BUREAU OF NARCOTICS & DANGEROUS DRUGS / U.S. DEPARTMENT OF JUSTICE / WASHINGTION, D.C. 20537 Vol.III, No. 2 March-April, 1970 STP (4-Methyl-2,5-dimethoxyamphetamine) hydrochloride was found coating the inside of capsules sent to BNDDfrom Germany. The capsules were clear, hard gelatin, standard shape size No. o. Average weight was 114 milligrams. Each capsule had a white crystalline coating on inner surface of capsule body. Apparently a measu~ed amount of solution had been placedin the cap·sule body, after which it was rotated to spread the solution on the inner surface. The substance contained 8. 7 milli­ grams STP (DOM)HCl per ca·psule. · These were the first STP capsules of this type seen by our laboratory. A few years ago, capsules were ob­ tained in the U.S. similarly coated with LSD. STP (Free Base) on laboratory filter paper, also from Germany, was seen for the first time in our laboratory. The STP spots, containing approxi­ mately 8 miliigrams STP base each, were 5/8 to 3/4 inch in diameter. The paper was 1\ inches square. Phencyclidine (Free Base) was recently analyzed on parsley leaves. Called "Angel DUst, 11 the phencyclidine on two samples of leaves was 2.6% and 3.6%. Approximately thirty pounds of 94% pure powder was also analyzed. (For identification of phencyclidine base, see Microgram, II, 1, p.3 (Jan 1969). IMITATIONSof well-known drug products are examined frequently in our Special Testing and Research Laboratory. Many of these are well made preparations and closely resemble the imitated product.
  • ACRITICAL ETHNOGRAPHY Paul Norman BENNETT

    ACRITICAL ETHNOGRAPHY Paul Norman BENNETT

    SATELLITE HAEMODIALYSIS NURSES’ PERCEPTIONS OF QUALITY NURSING CARE: A CRITICAL ETHNOGRAPHY Paul Norman BENNETT For the degree of Doctor of Philosophy in the School of Nursing and Midwifery Faculty of Health Sciences Flinders University, Adelaide, Australia August 2009 TABLE OF CONTENTS Declaration.................................................................................................................. x Acknowledgements....................................................................................................xi List of tables..............................................................................................................xii List of figures ............................................................................................................xii List of publications and presentations (relevant to the thesis but not forming part of it).................................................xiii Key to transcripts and field notes ..........................................................................xiv Abstract ..................................................................................................................... xv CHAPTER 1 SETTING THE SCENE: WHY EXPLORE SATELLITE DIALYSIS NURSES PERCEPTIONS OF QUALITY NURSING CARE? 1.1 Introducing the study.......................................................................................... 1 1.2 Chronic kidney disease: A global health issue................................................... 2 1.3 End stage kidney disease and dialysis: The Australian
  • Toxic Fungi of Western North America

    Toxic Fungi of Western North America

    Toxic Fungi of Western North America by Thomas J. Duffy, MD Published by MykoWeb (www.mykoweb.com) March, 2008 (Web) August, 2008 (PDF) 2 Toxic Fungi of Western North America Copyright © 2008 by Thomas J. Duffy & Michael G. Wood Toxic Fungi of Western North America 3 Contents Introductory Material ........................................................................................... 7 Dedication ............................................................................................................... 7 Preface .................................................................................................................... 7 Acknowledgements ................................................................................................. 7 An Introduction to Mushrooms & Mushroom Poisoning .............................. 9 Introduction and collection of specimens .............................................................. 9 General overview of mushroom poisonings ......................................................... 10 Ecology and general anatomy of fungi ................................................................ 11 Description and habitat of Amanita phalloides and Amanita ocreata .............. 14 History of Amanita ocreata and Amanita phalloides in the West ..................... 18 The classical history of Amanita phalloides and related species ....................... 20 Mushroom poisoning case registry ...................................................................... 21 “Look-Alike” mushrooms .....................................................................................